Conference abstract · 4 Apr 2024
Research articlePublished Oct 2020
Improving Access Through Biosimilar Trastuzumab
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Abstract Introduction: Most of the data available for approved biosimilars of trastuzumab are in form of RCT’s, this is the first observational clinical registry being conducted for Trastuzumab Biosimilar in India. Methods: This is an observational, drug utilization registry where data was collected for the patients eligible to receive trastuzumab biosimilar (Vivitra®, Cadila Healthcare). The data from 17 sites spreading pan India were collated using electronic data capturing system (21 CFR part 11 compliant. The study is registered in clinical trial Registry of India (CTRI/2018/05/013754) and conducted as per Good Clinical Practice. Results: The data were collected for 90 patients (89 female, 1 male) with Early Breast Cancer (EBC) treated with biosimilar trastuzumab, age range was 29-69 years. Fig 1 shows the pattern of trastuzumab dose cycle used in these EBC patients. Three weekly dose cycle was most commonly used. 84 patients had reported number of cycles with average of 11 treatment cycles (maximum of 24 cycles). 30 % patients completed the 17 treatment cycle protocol. There was varied usage of chemotherapeutic agents in these EBC patients as per Fig 2. Paclitaxel and docetaxel were most commonly used. 81 patients had Left Ventricular Ejection Fraction (LVEF) measured at before initiation of trastuzumab, out of which 74 had LVEF range between 55-70% and 7 had LVEF more than 70%. 59 patients out of 81 had post dose LVEF evaluation with none reporting LVEF < 55 % post dose. There was no discontinuation of the drug, all values for LVEF in post-dose phase for 59 subjects were reported in range of 55-74 %. There were 4 serious adverse events reported out of which 2 deaths were there. However deaths were unlikely due to the drug. Two cases of LVEF reduction were there which reversed on giving supporting care. Covids (CoV) are a huge group of infections that cause sickness going from the basic virus to more extreme illnesses, for example, Middle East Respiratory Syndrome (MERS-CoV) and Severe Acute Respiratory Syndrome (SARS-CoV-1). Another strain of Covid (SARS-CoV-2) causes Coronavirus malady 2019, or COVID-19, which was pronounced a pandemic by the WHO on 11 March 2020. Some Covids are zoonotic, which means they are communicated among creatures and individuals. Nitty gritty examinations found that SARS-CoV-1 was sent from civet felines to people, and MERS-CoV from dromedary camels to people. A few known Covids are flowing in creatures that have not yet tainted people. Basic indications of disease incorporate respiratory side effects, fever, hack, windedness, and breathing challenges. In more extreme cases, contamination can cause pneumonia, intense respiratory trouble disorder, kidney disappointment and even passing.
Subjects
Public Health & EpidemiologySimilar by topic
Article · 10 Nov 2022
The effectiveness and safety of trastuzumab biosimilar abp 980 plus pertuzumab and docetaxel in the therapy of her2 posi
Research article · 2022
The Effectiveness and Safety of Trastuzumab Biosimilar ABP 980 plus Pertuzumab and Docetaxel in the Therapy of HER-2 Positive Metastatic Breast Cancer: Real World Experiences from the National Research Institute of Oncology in Warsaw
Short communication · Jul 2018
Assessment of Structural and Functional Comparability of Biosimilar Products: Trastuzumab as a Case Study
Conference abstract · 27 Nov 2017
An Indian survey with oncologists for the use of biosimilar Trastuzumab in clinical practice
More from this journal
The newest in International Journal of Global Health.
Review article · Aug 2022
Influence of Patient Care Provider on the Effect of Self-Management Education Program on Glycemic Control: A Systematic Review Protocol
Editorial · Jan 2021
The relationship between parental characteristic and lead knowledge
Editorial · Jan 2021
Socioeconomic determinants of Parkinson's disease
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalInternational Journal of Global Health
- SubjectPublic Health & Epidemiology
- BylineArticles whose byline prints “Manish Mahajan”
